Dreavent Capital
Overview
Dreavent Capital is a venture capital firm that invests in biotech companies specializing in Oncology, Neurology, Cardiovascular & Metabolic, and Immunology sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Chimeron Bio | Feb 2022 | Seed | Co-investor |
| A4Cell | Nov 2023 | Series B | Lead |
| Astrocyte Pharmaceuticals Inc. | Aug 2023 | Early Funding | Lead |
| ACIRNA Therapeutics | Mar 2024 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Dreavent Capital based?
Dreavent Capital is headquartered in Cambridge, Massachusetts, United States.
When was Dreavent Capital founded?
Dreavent Capital was founded in 2020.
How many portfolio companies does Dreavent Capital have?
Dreavent Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in Dreavent Capital's portfolio?
Portfolio companies visible on Caplight include Chimeron Bio, A4Cell, Astrocyte Pharmaceuticals Inc., ACIRNA Therapeutics.
What was Dreavent Capital's most recent investment shown here?
Dreavent Capital's most recent investment in this portfolio sample was in ACIRNA Therapeutics in 2024.
What sectors does Dreavent Capital focus on?
Dreavent Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Dreavent Capital focus on?
Stage focus information for Dreavent Capital is not publicly available.